The transition from reactive to proactive oncology is being fueled by a paradigm shift in how we detect and treat malignancies. Central to this evolution is the utilization of biological indicators that provide a molecular "snapshot" of a patient’s health. As clinical practices increasingly integrate these diagnostic tools, the Cancer Biomarkers Market Size is set to undergo...